{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T20:25:24Z","timestamp":1757622324420,"version":"3.44.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.msard.2024.106175","type":"journal-article","created":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T12:20:30Z","timestamp":1731673230000},"page":"106175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Multiple Sclerosis and biological definitions in neurodegenerative diseases"],"prefix":"10.1016","volume":"92","author":[{"given":"Carlos R.","family":"Camara-Lemarroy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.msard.2024.106175_bib0001","doi-asserted-by":"crossref","first-page":"e16092","DOI":"10.1111\/ene.16092","article-title":"Treatment reduces the incidence of newly appearing multiple sclerosis lesions evolving into chronic active, slowly expanding lesions: a retrospective analysis","volume":"31","author":"Calvi","year":"2024","journal-title":"Eur. J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.106175_bib0002","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209444","article-title":"Using the progression independent of relapse activity framework to unveil the pathobiological foundations of multiple sclerosis","volume":"103","author":"Ciccarelli","year":"2024","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.msard.2024.106175_bib0003","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s00401-024-02742-w","article-title":"Disentangling the heterogeneity of multiple sclerosis through identification of independent neuropathological dimensions","volume":"147","author":"de Boer","year":"2024","journal-title":"Acta Neuropathol."},{"issue":"3","key":"10.1016\/j.msard.2024.106175_bib0004","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/WCO.0000000000001268","article-title":"Shifting our attention earlier in the multiple sclerosis disease course","volume":"37","author":"Epstein","year":"2024","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.msard.2024.106175_bib0005","series-title":"Presented at ECTRIMS 2024, Copenhagen, Denmark, Friday, 20 September","article-title":"Efficacy and safety of tolebrutinib versus placebo in non-relapsing secondary progressive multiple sclerosis: results from the phase 3 HERCULES trial","author":"Fox","year":"2024"},{"key":"10.1016\/j.msard.2024.106175_bib0006","series-title":"Presented at ACTRIMS Forum 2024, West Palm Beach, Florida, Saturday, March 1","article-title":"Primary outcome of a phase 2 clinical trial of tolebrutinib, a brain-penetrant BTK inhibitor, for the modulation of chronically inflamed white matter lesions in MS","author":"Gaitan","year":"2024"},{"issue":"6","key":"10.1016\/j.msard.2024.106175_bib0007","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus teriflunomide in multiple sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.msard.2024.106175_bib0008","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209884","article-title":"Challenges in a biological definition of Alzheimer disease","volume":"103","author":"Hazan","year":"2024","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.msard.2024.106175_bib0009","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S1474-4422(23)00404-0","article-title":"A biological classification of Parkinson's disease: the SynNeurGe research diagnostic criteria","volume":"23","author":"Hoglinger","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106175_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102173","article-title":"Revision of Alzheimer's diagnostic criteria or relocation of the Potemkin village","volume":"93","author":"H\u00f8ilund-Carlsen","year":"2024","journal-title":"Ageing Res. Rev."},{"issue":"8","key":"10.1016\/j.msard.2024.106175_bib0011","doi-asserted-by":"crossref","first-page":"5143","DOI":"10.1002\/alz.13859","article-title":"Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup","volume":"20","author":"Jack","year":"2024","journal-title":"Alzheimers. Dement."},{"issue":"10","key":"10.1016\/j.msard.2024.106175_bib0012","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1002\/mds.30007","article-title":"International parkinson and movement disorder society viewpoint on biological frameworks of parkinson's disease: current status and future directions","volume":"39","author":"Kalia","year":"2024","journal-title":"Mov. Disord."},{"issue":"4","key":"10.1016\/j.msard.2024.106175_bib0013","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1177\/13524585211031801","article-title":"MRI brain volume loss, lesion burden, and clinical outcome in secondary progressive multiple sclerosis","volume":"28","author":"Koch","year":"2022","journal-title":"Mult. Scler."},{"issue":"1","key":"10.1016\/j.msard.2024.106175_bib0014","doi-asserted-by":"crossref","first-page":"7670","DOI":"10.1038\/s41467-022-35357-4","article-title":"Molecular models of multiple sclerosis severity identify heterogeneity of pathogenic mechanisms","volume":"13","author":"Kosa","year":"2022","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.msard.2024.106175_bib0015","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","article-title":"Bruton tyrosine kinase inhibitors for multiple sclerosis","volume":"19","author":"Kr\u00e4mer","year":"2023","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2024.106175_bib0016","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1474-4422(22)00289-7","article-title":"Multiple sclerosis progression: time for a new mechanism-driven framework","volume":"22","author":"Kuhlmann","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106175_bib0017","series-title":"Presented at ECTRIMS 2024, Copenhagen, Denmark, Thursday, 19 September","article-title":"New course descriptors","author":"Lublin","year":"2024"},{"issue":"10","key":"10.1016\/j.msard.2024.106175_bib0018","doi-asserted-by":"crossref","first-page":"3817","DOI":"10.1007\/s00415-021-10501-0","article-title":"Long-term analysis of patients with benign multiple sclerosis: new insights about the disability course","volume":"268","author":"Mathey","year":"2021","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2024.106175_bib0019","series-title":"Presented at ECTRIMS 2024, Copenhagen, Denmark, Wednesday, 18 September","article-title":"Revised McDonald criteria 2023","author":"Montalban","year":"2024"},{"issue":"11","key":"10.1016\/j.msard.2024.106175_bib0020","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1001\/jamaneurol.2023.3331","article-title":"Harmonizing definitions for progression independent of relapse activity in multiple sclerosis: a systematic review","volume":"80","author":"M\u00fcller","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2024.106175_bib0021","series-title":"Presented at ECTRIMS 2024, Copenhagen, Denmark, Friday, 20 September","article-title":"Efficacy and safety of tolebrutinib versus teriflunomide in relapsing multiple sclerosis: results from the phase 3 GEMINI 1 and 2 trials","author":"Oh","year":"2024"},{"issue":"23","key":"10.1016\/j.msard.2024.106175_bib0022","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1161\/CIRCULATIONAHA.120.044221","article-title":"HDL in the 21st century: a multifunctional roadmap for future HDL research","volume":"143","author":"Rohatgi","year":"2021","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.msard.2024.106175_bib0023","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/S1474-4422(23)00405-2","article-title":"A biological definition of neuronal alpha-synuclein disease: towards an integrated staging system for research","volume":"23","author":"Simuni","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.msard.2024.106175_bib0024","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER). Early Alzheimer's disease: developing drugs for treatment guidance for industry. 2024. fda.gov\/regulatory information\/search-fdaguidance-documents\/early-alzheimers-disease-developing-drugs-treatment."},{"issue":"1","key":"10.1016\/j.msard.2024.106175_bib0025","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1038\/s41582-021-00581-x","article-title":"Mechanism-based criteria to improve therapeutic outcomes in progressive multiple sclerosis","volume":"18","author":"Yong","year":"2022","journal-title":"Nat. Rev. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400751X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482400751X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T18:56:55Z","timestamp":1757357815000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482400751X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":25,"alternative-id":["S221103482400751X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2024.106175","relation":{},"ISSN":["2211-0348"],"issn-type":[{"type":"print","value":"2211-0348"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Multiple Sclerosis and biological definitions in neurodegenerative diseases","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2024.106175","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106175"}}